MedTrace Logo

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT02282930 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-06-26

Study results available
· View outcomes & findings →

Summary

This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.

Conditions

  • Progressive IgA Nephropathy
  • Proteinuria

Interventions

DRUG

ACTH (Acthar) Gel

Injected dose of 80 units subcutaneously twice weekly for 6 months.

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Fernando Fervenza, MD, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282930 on ClinicalTrials.gov